Morningstar

Alnylam Pharmaceuticals Inc ALNY

Morningstar Rating
Unlock
Stock XNAS Rating as of
$271.55 −4.51 (1.63%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Narrow-Moat Alnylam's Positive Data in Vutrisiran ATTR-CM Trial Should Drive Strong Long-Term Growth

Rachel Elfman

Alnylam Pharmaceuticals is a pioneer in designing therapeutics based on RNA interference, or RNAi, a mechanism that occurs naturally in cells and silences overexpressed genes, which often cause protein misfolding and/or protein accumulation. Alnylam seeks to capitalize on the therapeutic potential of RNAi by creating small interfering RNA, or siRNA, that can treat diseases at the genetic level. When siRNA reaches its intended target, it can silence the gene that it contains code for, making it a potentially game-changing technology for difficult- to-treat diseases caused by genetic mutations.

Read Full Report

Price vs Fair Value

View History
ALNY is trading at a 38% premium.
Price
$271.55
Fair Value
$424.00
Uncertainty
High
1-Star Price
$275.22
5-Star Price
$379.10
Economic Moat
Vqbllj
Capital Allocation
Hhbggqbg

Bulls Say, Bears Say

Bulls

Alnylam's Nobel-prize-winning technology and massive intellectual property in RNA interference helped the firm create an entirely new class of therapeutics for difficult to treat diseases.

Bears

Alnylam's valuation rests on its ability to maintain six-figure pricing and payers' willingness to continue reimbursement, which could be affected by shifts in healthcare drug policy.

Show More

News

View All

Trading Information

Previous Close Price
$276.06
Day Range
$264.84–276.50
52-Week Range
$141.98–287.55
Bid/Ask
$271.49 / $277.54
Market Cap
$34.86 Bil
Volume/Avg
552,825 / 865,051

Key Statistics

Price/Earnings (Normalized)
154.14
Price/Sales
14.59
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees
2,100
Website
https://www.alnylam.com

Competitors

Valuation

View More
Metric
ALNY
IONS
INCY
Price/Earnings (Normalized)
 154.14—16.51
Price/Book Value
 —21.814.32
Price/Sales
 14.597.003.92
Price/Cash Flow
 66.98—96.17
Price/Earnings
ALNY
IONS
INCY

Financial Strength

Metric
ALNY
IONS
INCY
Quick Ratio
 2.786.881.69
Current Ratio
 3.017.611.92
Interest Coverage
 −0.35−3.0964.57
Quick Ratio
ALNY
IONS
INCY

Profitability

Metric
ALNY
IONS
INCY
Return on Assets (Normalized)
 5.94%−8.75%3.60%
Return on Equity (Normalized)
 —−74.23%4.83%
Return on Invested Capital (Normalized)
 21.50%−10.19%1.61%
Return on Assets
ALNY
IONS
INCY

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk AS ADR
NVO
JdkwzqdslvQghwf$518.0 Bil
 Vertex Pharmaceuticals Inc
VRTX
CrgymndmTyxzbhl$119.3 Bil
 Regeneron Pharmaceuticals Inc
REGN
LrsftvfnQkyvt$114.7 Bil
 argenx SE ADR
ARGX
JtnflcxcZwhz$32.9 Bil
 BioNTech SE ADR
BNTX
RwwcvtvqLmtf$28.3 Bil
 Moderna Inc
MRNA
BjtdhztdcHnhg$24.3 Bil
 United Therapeutics Corp
UTHR
XcdmyxyWcy$15.7 Bil
 Biomarin Pharmaceutical Inc
BMRN
WmxsqvrjMgzljzt$13.3 Bil
 Incyte Corp
INCY
YfxfkpxRhpmbwh$13.0 Bil

Sponsor Center